Why do patients with myositis die? A retrospective analysis of a single-centre cohort

Clinical and Experimental Rheumatology

Volumn 34, Issue 5, 2016, Pages 820-826

  Silva, Marta Amaral ^a   Cogollo, Estefania ^b   Isenberg, David A ^c  

^a Pediatric Department Figueira da Foz Hospital   (Portugal)

^b HOSPITAL UNIVERSITARIO PRÍNCIPE DE ASTURIAS   (Spain)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Causes of death; Extramuscular complications; Inflammatory myopathies; Long term survival; Predictors of poor prognosis

Indexed keywords

ANTINUCLEAR ANTIBODY; AZATHIOPRINE; CREATINE KINASE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; JO 1 ANTIBODY; METHOTREXATE; STEROID;

ADULT; ADULT ONSET DERMATOMYOSITIS; ADULT ONSET POLYMYOSITIS; ARTICLE; CALCINOSIS; CAUCASIAN; CAUSE OF DEATH; CHRONIC DISEASE; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DERMATOMYOSITIS; DISEASE COURSE; DYSPHAGIA; FEMALE; FEMALE GENITAL TRACT CANCER; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL DISEASE; GASTROINTESTINAL HEMORRHAGE; HEART ARRHYTHMIA; HEART DISEASE; HEART INFARCTION; HEART MUSCLE CONDUCTION DISTURBANCE; HEMATOLOGIC DISEASE; HODGKIN DISEASE; HUMAN; INCLUSION BODY MYOSITIS; INFECTION; INFLAMMATORY CELL; INJURY; INTERSTITIAL LUNG DISEASE; ISCHEMIC HEART DISEASE; JUVENILE RHEUMATOID ARTHRITIS; LIMB WEAKNESS; LUNG CANCER; LUNG DISEASE; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; MORTALITY RATE; MUSCLE WEAKNESS; MYOSITIS; OBSERVATIONAL STUDY; OVERLAP MYOSITIS; PNEUMONIA; POLYMYOSITIS; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PULMONARY HYPERTENSION; RETROSPECTIVE STUDY; SEPSIS; SEROLOGY; SKIN ULCER; SURVIVAL RATE; TREATMENT OUTCOME; VALVULAR HEART DISEASE; COMMUNICABLE DISEASE; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; MULTIVARIATE ANALYSIS; PROPORTIONAL HAZARDS MODEL; RISK FACTOR; TIME FACTOR; YOUNG ADULT;

ADULT; CAUSE OF DEATH; COMMUNICABLE DISEASES; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LUNG DISEASES; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; MYOSITIS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK FACTORS; TIME FACTORS; YOUNG ADULT;

EID: 84988329775     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. BOHAN A, PETER JB: Polymyositis and dermatomyositis. Parts 1 and 2. New Engl J Med 1975; 292: 344-7, 403-7.
2. DORPH C, LUNDBERG IE: Idiopathic inflammatory myopathies-myositis. Best Pract Res Clin Rheumatol 2002; 16: 817-32.
3. TABORDA AL, AZEVEDO P, ISENBERG DA: Retrospective analysis of the outcome of patients with idiopathic inflammatory myopathy: a long-term follow-up study. Clin Exp Rheumatol 2014; 32: 188-93.
4. LANDBERG IE, FORBESS CJ: Mortality in idiopathic inflammatory myopathies. Clin Exp Rheumatol 2008; 26: 109-14.
5. BARSOTTI S, TERENZI R, LA PAGLIA GMC, BELLUCCI E, BALDINI C, NERI R: One year in review 2015: idiopathic inflammatory myopathies. Clin Exp Rheumatol 2015; 33: 593-601.
6. CASTRO C, GOURLEY M: Diagnosis and treatment of inflammatory myopathy: issues and management. Ther Adv Musculoskelet Dis 2011; 4: 111-20.
7. MALDONADO F, PATEL RR, IYER VN, YI ES, RYU JH: Are respiratory complications common causes of death in inflammatory myopathies? An autopsy study. Respirology 2012; 17: 455-60.
8. SANTO AH, SOUZA JMP, PINHEIRO CE, SOUZA DC, SATO EI: Trends in dermatomyositis-and polymyositis-related mortality in the state of São Paulo, Brazil, 1985-2007: multiple cause-of-death analysis. BMC Public Health 2010; 10: 597.
9. TORRES C, BELMONTE R, CARMONA L et al.: Survival, mortality and causes of death in inflammatory myopathies. Autoimmunity 2006; 39: 205-15.
10. LIMAYE V, HAKENDORF P, WOODMAN RJ: Mortality and its predominant causes in a large cohort of patients with biopsy-determined inflammatory myositis. Intern Med J 2012; 42: 191-8.
11. BENBASSAT J, GEFEL D, LARHOLT K, SUKENIK S, MORGENSTERN V, ZLOTNICK A: Prognostic factors in polymyositis/dermatomyositis. A computer-assisted analysis of ninetytwo cases. Arthritis Rheum 1985; 28: 249-55.
12. MEDSGER TA, ROBINSON H, MASI AT: Factors affecting survivorship in polymyositis. A life table study of 124 patients. Arthritis Rheum 1971; 14: 249-58.
13. HOCHBERG MC, FELDMAN D, STEVENS MB: Adult onset Polymyositis-Dermatomyositis: An analysis of Clinical and Laboratory Features and Survival in 76 patients with a review of the literature. Semin Arthritis Rheum 1986; 15: 168-78.
14. LU Z, GUO-CHUN W, LI M, NING, Z: Cardiac Involvement in Adult Polymyositis or Dermatomyositis: A Systematic Review. Clin Cardiol 2012; 35: 686-91.
15. SALVADOR FB, ISENBERG DA: Outcome predictors in patients with idiopathic inflammatory myopathies. Clin Exp Rheumatol 2012; 30: 980.
16. AIRIO A, KAUTIAINEN H, HAKALA M: Prognosis and mortality of polymyositis and dermatomyositis. Clin Rheumatol 2006; 25: 234-9.
17. DANKO K, PONYI A, CONSTANTIN T: Long-Term survival of patients with idiopathic inflammatory myopathies according to clinical features: a longitudinal study of 162 cases. Medicine 2004; 83: 35-42.
18. MARIE I, HACHULLA E, HATRON PY et al.: Polymyositis and dermatomyositis: short term and longterm outcome, and predictive factors of prognosis. J Rheumatol 2001; 28: 2230-7.
19. MAUGARS YM, BERTHELOT JM, ABBAS AA, MUSSINI JM, NGUYEN JM, PROST AM: Longterm prognosis of 69 patients with dermatomyositis or polymyositis. Clin Exp Rheumatol 1996; 14: 263-74.
20. BRONNER IM, van der MEULEN MFG, de VISSER M et al.: Long-term outcome in polymyositis and dermatomyositis. Ann Rheum Dis 2006; 65: 1456-61.
21. SCHIOPU E, PHILLIPS K, MacDONALD P, CROFFORD LJ, SOMERS EC: Predictors of survival in a cohort of patients with polymyositis and dermatomyositis: effect of corticosteroids, methotrexate and azathioprine. Arthritis Res Ther 2012; 14: 22-31.
22. LYNN SJ, SAWYERS SM, MOLLER PW, O'DONNELL JL, CHAPMAN PT: Adult-onset inflammatory myopathy: North Canterbury experience 1989-2001. Intern Med J 2005; 35: 170-3.
23. MARIE I, MENARD JF, HACHULLA E et al.: Infectious Complications in Polymyositis and Dermatomyositis: A Series of 279 Patients. Semin Arthritis Rheum 2011; 41: 48-60.
24. TANI K, TOMIOKA R, SATO K et al.: Comparison of clinical course of polymyositis and dermatomyositis: a follow-up in Tokushima University Hospital. J Med Invest 2007; 54: 295-302.
25. MARIE I, HACHULLA E, CHERIN P et al.: Interstitial Lung Disease in Polymyositis and Dermatomyositis. Arthritis Rheum 2002; 47: 614-22.
26. SCHNABEL A, REUTER M, BIEDERER J: Interstitial lung disease in polymyositis and dermatomyositis: clinical course and response to treatment. Semin Arthritis Rheum 2003; 32: 273-84.
27. KAPLAN MJ: Endothelial damage and autoimmune diseases. Autoimmunity 2009; 42: 561-2.
28. GUNDOGDU BM, CILINGIROGLU M: Chronic inflammatory muscle diseases and risk of coronary artery disease. Curr Atheroscler Rep 2011; 15: 308.
29. SIGURGEIRSSON B, LINDELöF B, EDHAG O, ALLANDER E: Risk of cancer in patients with dermatomyositis or polymyositis. A population-based study. N Engl J Med 1992; 326: 363-7.
30. MARIE I, GUILLEVIN L, MENARD JF et al.: Hematological malignancy associated with polymyositis and dermatomyositis. Autoimmun Rev 2012; 11: 615-20.
31. BUCHBINDER R, FORBES A, HALL S, DENNETT X, GILES G: Incidence of malignant disease in biopsy-proven inflammatory myopathy. A population-based cohort study. Ann Intern Med 2001; 134: 1087-95.
32. ANDRAS C, PONYI A, CONSTANTIN T et al.: Dermatomyositis and polymyositis associated with malignancy: a 21-year retrospective study. J Rheumatol 2008; 35: 438-44.
33. KOH ET, SEOW A, ONG B, RATNAGOPAL P, TJIA H, CHNG HH: Adult onset polymyositis/ dermatomyositis: clinical and laboratory features and treatment response in 75 patients. Ann Rheum Dis 1993; 52: 857-61.
34. MARIE I, HATRON PY, LEVESQUE H et al.: Influence of age on characteristics of polymyositis and dermatomyositis in adults. Medicine 1999; 78: 139-47.
35. VIGUIER M, FOUÉRÉ S, de la SALMONIÈRE P et al.: Peripheral blood lymphocyte subset counts in patients with dermatomyositis. Clinical correlations and changes following therapy. Medicine 2003; 82: 82-6.
36. LOVE LA, LEFF RL, FRASER DD et al.: A new approach to the classification of idiopathic inflammatory myopathy: myositis-specific autoantibodies define useful homogeneous patient groups. Medicine 1991; 70: 360-74.
37. HENGSTMAN GJ, BROUWER R, EGBERTS WT et al.: Clinical and serological characteristics of 125 Dutch myositis patients. Myositis specific autoantibodies aid in the differential diagnosis of the idiopathic inflammatory myopathies. J Neurol 2002; 249: 69-75.
38. ARSURA EL, GREENBERG AS: Adverse impact of interstitial pulmonary fibrosis on prognosis in polymyositis and dermatomyositis. Semin Arthritis Rheum 1988; 18: 29-37.
39. CHEN IJ, JAN WU YJ, LIN CW et al.: Interstitial lung disease in polymyositis and dermatomyositis. Clin Rheumatol 2009; 28: 639-46.